Mizuho Downgrades Rain Oncology to Neutral, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh downgraded Rain Oncology (NASDAQ:RAIN) from Buy to Neutral and lowered the price target from $17 to $1.
June 05, 2023 | 9:11 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rain Oncology downgraded to Neutral by Mizuho, with a lowered price target of $1 from $17.
The downgrade from Buy to Neutral by Mizuho analyst Graig Suvannavejh and the significant reduction in the price target from $17 to $1 indicate a negative outlook for Rain Oncology's stock price in the short term. This news is likely to impact investor sentiment and could lead to a decline in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100